Omar Adwan: The Diagnostic Value of Schistocytes in Hemolytic Disorders
Omar Adwan, Medical Laboratory Technologist at Modawah Lab Center, shared a post on LinkedIn:
“Schistocyte
A schistocyte is a fragmented red blood cell that results from mechanical damage as it passes through abnormal or narrowed blood vessels, such as those with microthrombi or damaged endothelium.
It is a key marker of Microangiopathic Hemolytic Anemia (MAHA), a condition where red blood cells are destroyed within the circulation.
Morphological Variants of Schistocytes.
Helmet Cell
- Resembles a helmet with a smooth curved edge and a sharp indentation
- Formed when part of the cell is sheared off by fibrin strands
- Commonly seen in DIC, TTP, and HUS
Triangle Cell / Triangular Fragment
- Appears triangular, or sometimes trapezoidal
- Produced by fragmentation in multiple directions
- Reflects severe and irregular RBC destruction
Crescent Cell / Semilunar Cell
- Shaped like a crescent moon
- Usually found in cases of severe red cell fragmentation
Keratocyte (Horn Cell)
- Has horn-like or spiked projections
- Formed when a cell is pinched and torn, then re-fuses partially
- Seen in MAHA and sometimes in hemolysis caused by prosthetic heart valves
Micro spherocyte like Fragments
- Small, round RBC fragments without central pallor
- Resemble microspherocytes but result from fragmentation, not membrane loss
- Smaller and denser than normal RBCs
Blister Cell
- Shows a blister-like vacuole resembling an air bubble
- Considered a precursor stage before forming a bite cell or schistocyte
- Often seen in the early phase of mechanical RBC damage
Clinical Significance
The presence of schistocytes on a blood smear is an important hematologic emergency warning sign.
- If schistocytes are greater than 1 percent or present in large numbers, MAHA should be strongly suspected.
- Associated conditions include TTP, HUS, DIC, HELLP syndrome, and prosthetic heart valve–induced hemolysis.”
Other posts featuring Omar Adwan on Hemostasis Today.
-
Jul 1, 2026, 14:04Sinju Thomas: Strengthening Apheresis Excellence Through Shared Learning
-
Jul 1, 2026, 14:02Nikola Pantic: Advances in Diagnosis and Treatment of Hematological Diseases
-
Jul 1, 2026, 13:47Mostafa Faisal: Advancing Care in β-Thalassemia With Luspatercept
-
Jul 1, 2026, 13:40Tran-Hai-Yen Nguyen: Connecting with the Global Blood Transfusion Community at ISBT 2026
-
Jul 1, 2026, 13:29Farjah Algahtani: Joining the Global Conversation at ISTH 2026
-
Jul 1, 2026, 12:14Ney Carter Borges: Simplifying Blood Pressure Control After Intracerebral Hemorrhage
-
Jul 1, 2026, 12:11Ifeanyichukwu Ifechidere: DOAC Monitoring – What To Order, When, And Why
-
Jul 1, 2026, 12:01Nathan Connell: Tranexamic Acid – Small Intervention, Big Impact
-
Jul 1, 2026, 08:48R.R. Baliga: The New JACC/ACC 2026 Statement Reinforces That DOAC Therapy Is Never One Size Fits All